PANAPHIX

Welcome to the Brand page for “PANAPHIX”, which is offered here for Germicides; pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibiotic preparations; chemotherapy medicines; tumor suppressing agents; pharmaceutical preparations acting on the central nervous system; cardiovascular pharmaceutical agents; pharmaceutical agents affecting metabolism; chemical preparations for pharmaceutical purposes, for the treatment of pain and inflammation associated with cancer, the treatment of cancer, the treatment of leukemia and lymphoma, the treatment of metastatic neoplastic diseases, the treatment brain tumors, cancer stem cell-targeted and drug resistant cancer therapy, the treatment of urogenital cancer and its metastasis; biological preparations for the treatment of porcine circoviral disease, porcine epidemic diarrhea, transmissible gastroenteritis, rotavirus infection pasteurellosis, pleuropneumoniae, classical swine fever, swine erysipelas, swine mycoplasmoses, akabane disease, pasteurellosis, colibacillosis, bovine ephemeral fever, newcastle disease, infectious bronchitis, low pathogenicity avian influenza, infectious bursal disease, salmonellosis, rabies, canine distemper, infectious canine hepatitis, parvovirus infection, coronavirus infection, leptospirosis;.

Its status is currently believed to be active. Its class is unavailable. “PANAPHIX” is believed to be currently owned by “Komipharm International Co., Ltd.”